

electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submissions of responses.

DATES: Written comments must be submitted to the office listed in the **ADDRESSES** section by December 24, 2001.

ADDRESSES: Send comments to: Corporation for National and Community Service, Attn. William Ward, Office of Evaluation, 9th Floor, 1201 New York Avenue, NW., Washington, DC 20525.

FOR FURTHER INFORMATION CONTACT: William Ward, (202) 606-5000, ext. 375.

SUPPLEMENTARY INFORMATION:

AmeriCorps Education Award Utilization Survey

Background

One of the goals of the AmeriCorps program is furthering the educational opportunities of its members. The AmeriCorps Education Award provides up to \$4,725 to help a member pay for further education or to repay student loans. Part-time members get a pro-rated portion of that amount. The Corporation's National Service Trust data showed that about half of the AmeriCorps graduates who have earned Education Awards had begun to use them. Through the proposed study, the Corporation seeks to identify reasons for non-use of Education Awards. In addition, a thorough exploration of trends in non-use and reasons for non-use will identify ways in which the Corporation can meaningfully increase the use of Education Awards, thus furthering educational opportunity.

Current Action

The Corporation seeks to conduct a survey of former members of the AmeriCorps*State and National, AmeriCorps*VISTA and AmeriCorps*NCCC programs. This survey will entail telephone interviews of approximately 30 minutes in length with 1,000 former AmeriCorps members. It will identify trends in and reasons for non-use of the Educational Awards.

- *Type of Review:* New collection.
- *Agency:* Corporation for National and Community Service.
- *Title:* AmeriCorps Education Award Utilization Survey.
- *OMB Number:* None.
- *Agency Number:* None.
- *Affected Public:* Former AmeriCorps members.
- *Total Respondents:* 1,000.
- *Frequency:* One time.

- *Average Time Per Response:* 30 minutes.
- *Estimated Total Burden Hours:* 500 hours.
- *Total Burden Cost (capital/startup):* 0
- *Total Burden Cost (operating/maintenance):* 0

Comments submitted in response to this notice will be summarized and/or included in the request for Office of Management and Budget approval of the information collection request; they will also become a matter of public record.

Dated: October 18, 2001.

David Rymph,

Acting Director, Department of Evaluation and Effective Practices.

[FR Doc. 01-26669 Filed 10-22-01; 8:45 am]

BILLING CODE 6050--\$-P

DEPARTMENT OF DEFENSE

Department of the Army

Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Detection of Antibodies to Squalene in Serum

AGENCY: U.S. Army Medical Research and Materiel Command, DOD.

ACTION: Notice.

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the availability for licensing of U.S. Patent Application No. 09/859,389 entitled "Detection of Antibodies to Squalene in Serum" filed May 18, 2001. This patent has been assigned to the United States Government as represented by the Secretary of the Army.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, Maryland 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664. Both at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: The invention is a method for detecting squalene in sera.

Luz D. Ortiz,

Army Federal Register Liaison Officer.

[FR Doc. 01-26675 Filed 10-22-01; 8:45 am]

BILLING CODE 3710-08-M

DEPARTMENT OF DEFENSE

Department of the Army

Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Method of Inhibiting Side Effects of Pharmaceutical Compositions Containing Amphiphilic Vehicles or Drug Carrier Molecules

AGENCY: U.S. Army Medical Research and Materiel Command, DOD.

ACTION: Notice.

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the availability for licensing of U.S. Patent Application No. 09/183,375 entitled "Method of Inhibiting Side Effects of Pharmaceutical Compositions Containing Amphiphilic Vehicles or Drug Carrier Molecules" filed October 30, 1998. Foreign rights are also available (PCT/US98/23280). This patent has been assigned to the United States Government as represented by the Secretary of the Army.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, Maryland 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664. Both at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: A method is provided for inhibiting or preventing toxicity and other unwanted effects (a) caused by solvents for pharmaceuticals which solvents or emulsifier contain amphiphilic molecules such as polyethoxylated oils or a derivative thereof, or (b) caused by a drug in a vehicle containing amphiphilic molecules such as phospholipids or derivative thereof, employing a complement inhibitor, and pharmaceutical compositions including a drug, solvent, or carrier containing amphiphilic molecules or derivatives thereof, and a complement inhibitor are also provided.

Luz D. Ortiz,

Army Federal Register Liaison Officer.

[FR Doc. 01-26674 Filed 10-22-01; 8:45 am]

BILLING CODE 3710-08-M